Last update 19 Apr 2025

IBR854

Overview

Basic Info

Drug Type
CAR-NK
Synonyms
CAR-raNK, Conjugated Antibody Redirecting ready-to-use allogeneic NK cells, IBR 854
+ [2]
Target
5T4
Action
modulators
Mechanism
5T4 modulators(Trophoblast glycoprotein modulators), Gene transference, Natural killer cell replacements
Therapeutic Areas
NeoplasmsDigestive System DisordersUrogenital Diseases
Active Indication
Locally Advanced Malignant Solid NeoplasmLiver CancerAdvanced Renal Cell Carcinoma
Inactive Indication-
Originator Organization
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
Active Organization
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with IBR854
NCT06001684
/ RecruitingPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors
CTR20231412
/ RecruitingPhase 1
评价IBR854细胞注射液在不可切除的局部晚期或转移性实体肿瘤患者中的安全性、耐受性及初步疗效的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability and preliminary efficacy of IBR854 cell injection in patients with unresectable locally advanced or metastatic solid tumors
NCT05137275
/ Unknown statusEarly Phase 1IIT
Dose Escalation and Extension Study to Evaluate the Safety, Tolerability, and Initial Efficacy of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with IBR854
Login to view more data
100 Translational Medicine associated with IBR854
Login to view more data
100 Patents (Medical) associated with IBR854
Login to view more data
100 Deals associated with IBR854
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 1
China
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
01 Sep 2023
Liver CancerPhase 1
China
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
31 Aug 2023
Advanced Renal Cell CarcinomaIND Approval
China
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
18 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free